How Much Will the Wegovy Pill Cost in the UK? Expected Price, NHS Access and Injection Comparison
Last updated: 16 June 2026
The Wegovy pill has been approved in the UK, but Novo Nordisk has not announced how much it will cost. Based on confirmed US pricing, existing UK oral semaglutide pricing (Rybelsus), current UK Wegovy injection prices, and the commercial risk of cannibalising injection sales, our estimate is that the Wegovy pill could cost around £179 to £229 per month once it launches privately in the UK, with a broader plausible range of roughly £149 to £250.
This is a commercial estimate, not an official Novo Nordisk price, and it is not medical advice. No official manufacturer price has been confirmed. Any provider estimate or pre-launch price may change.
Wegovy, Rybelsus and Mounjaro are prescription-only medicines. This article provides general pricing information and does not recommend any medicine. Supply requires an appropriate clinical assessment and prescription. Treatment decisions, including any change of formulation or dose, should be made with a qualified prescriber, taking account of suitability, potential adverse effects and monitoring requirements. Do not buy these medicines from social media or from any seller offering supply without a prescription.
At a glance
- UK Wegovy pill price: not announced
- MHRA approval date: 11 June 2026
- NHS availability: not currently available
- Most likely private price (our estimate): £179 to £229/month
- Confirmed US launch price: $149 to $299/month by dose
- Closest UK pricing precedent: Rybelsus (oral semaglutide), representative range £175 to £280/month by dose, observed June 2026
How we estimated the price
This estimate is based on: confirmed US Wegovy tablet pricing; current UK Wegovy injection pricing; current UK Rybelsus pricing; Mounjaro pricing and competition; Novo Nordisk's commercial incentives; and NHS list pricing data where available. No official UK Wegovy pill price has been announced.
Has Novo Nordisk Announced the UK Price of Wegovy Tablets?
No. It's worth separating three stages that get conflated constantly: MHRA approval, commercial launch, and NHS reimbursement.
The MHRA's own announcement confirms that, alongside a reduced-calorie diet and increased physical activity, the semaglutide tablet may now be prescribed to UK adults with a BMI of 30 or above, or a BMI of 27 or above but below 30 with at least one weight-related comorbidity, following a dose-escalation schedule from 1.5mg up to 25mg. It also states that patients already receiving the 2.4mg weekly injection privately may be transitioned to the 25mg tablet. Any dose escalation or transition must be directed by a prescriber. Patients should not change formulation or dose themselves. The authorisation was granted on 11 June 2026.
Unlike the weekly injection, oral semaglutide must generally be taken on an empty stomach with a small amount of water, with patients then waiting at least 30 minutes before eating or drinking. Patients should follow the patient information leaflet and their prescriber's instructions, including advice about other medicines. The daily administration routine differs from a once-a-week injection, so price alone may not determine which formulation is suitable for an individual.
Commercial launch is separate. Approval doesn't mean stock is sitting in pharmacy warehouses. Industry coverage has reported a launch window in the second half of 2026 for select markets, and UK providers including Superdrug Online Doctor have opened registers for launch notifications. As of the approval date, the tablet had not yet launched commercially in the UK, and pricing for that private launch has not been disclosed.
NHS reimbursement is separate. The MHRA's announcement is explicit that the tablet is not currently available via the NHS, and that decisions on NHS use will follow established processes, including a NICE evaluation. The timing of any NHS availability has not been confirmed and will be separate from the private commercial launch.
What Rybelsus Pricing Tells Us About the Wegovy Pill Price
Most coverage of this topic focuses on US pricing. However, the closest UK precedent may actually be Rybelsus, since it tells us something the US figures can't.
Novo Nordisk isn't pricing an oral semaglutide tablet in the UK for the first time. It already sells one: Rybelsus, a once-daily semaglutide tablet, taken under broadly similar fasting conditions to the new Wegovy pill and currently licensed in the UK for type 2 diabetes, not weight management. Comparing Rybelsus pricing against Wegovy injection pricing gives us a real-world look at how Novo Nordisk and UK pharmacies have priced an oral semaglutide product relative to the injectable. However, the products have different licensed indications and should not be treated as equivalent treatment options.
| Product | Active ingredient | Format | Typical UK private price (per month) | Basis |
|---|---|---|---|---|
| Rybelsus 3mg | Semaglutide | Tablet | £175 to £210 | Reported range across UK private providers |
| Rybelsus 7mg | Semaglutide | Tablet | £185 to £245 | Reported range across UK private providers |
| Rybelsus 14mg | Semaglutide | Tablet | £195 to £280 | Reported range across UK private providers |
| Wegovy 0.25mg (starter) | Semaglutide | Injection | £80 to £120 | Reported range across UK GPhC-registered providers |
| Wegovy 1.7mg | Semaglutide | Injection | £125 to £155 | Reported range across UK GPhC-registered providers |
| Wegovy 2.4mg (maintenance) | Semaglutide | Injection | £145 to £300 | Reported range across UK GPhC-registered providers |
These are representative UK private pricing ranges observed in June 2026, drawn from published pricing at multiple UK private and online pharmacy providers. They are not a single live price check across named providers and are not exact market prices. Individual quotes vary and change frequently, so confirm the current price directly with a provider. Rybelsus is not licensed for weight management in the UK, so its pricing should not be treated as a like-for-like comparison with medicines licensed for that purpose.
The pattern that stands out is that Rybelsus, the existing oral semaglutide tablet, is not consistently priced below the Wegovy injection. At several UK providers it is priced at or above the injection's starter and mid-range doses, and is broadly comparable to maintenance-dose injection pricing at typical mid-market rates. This is a pricing comparison only. The products have different licensed indications and are not directly comparable as treatments.
We want to be careful about how much weight this evidence can bear. Rybelsus is licensed for type 2 diabetes, not weight management, and its commercial context differs from that of the new tablet. While Rybelsus is not a direct pricing blueprint for the Wegovy pill, its pricing suggests that oral semaglutide has not historically been positioned as a low-cost alternative to injectable semaglutide in the UK. That is a relevant commercial data point, but it cannot be treated as a confirmed precedent for how the new tablet will be priced.
How Much Does Wegovy Injection Cost in the UK?
UK private pricing for injectable Wegovy varies considerably by provider and dose:
| Dose stage | Typical UK private price (per month) |
|---|---|
| Starter doses (0.25mg to 1mg) | £80 to £180 |
| Mid-range doses (1.7mg) | £125 to £250 |
| Maintenance doses (2.4mg) | £145 to £300+ |
The NHS list price for the 2.4mg maintenance pen is reported at around £175.80 for a four-week supply, which gives a sense of where the manufacturer's own list pricing sits before private pharmacy margins are added.
The spread across providers comes down to pharmacy margins, whether consultations are bundled into the price, provider pricing policies, and periods of UK supply tightness. This existing injection price range, roughly £150 to £250 for many maintenance-dose patients, is one benchmark against which any tablet price may be assessed.
How Much Does the Wegovy Pill Cost in the United States?
The US is the only market where the tablet is already commercially available, having launched on 5 January 2026. According to Novo Nordisk's announcement, self-pay pricing starts at $149 a month for the 1.5mg dose. The 4mg dose was priced at $149 a month through 15 April 2026 and at $199 a month after that date, while the highest-dose tablets are priced at $299 a month.
These are discounted cash-pay figures for a US market with no direct UK equivalent in insurance structure. We therefore treat them as evidence of pricing direction, rather than evidence of the exact price or discount the UK may see.
What Novo Nordisk's US Pricing Strategy May Reveal
It's worth looking more closely at the shape of the confirmed US pricing rather than just the endpoints. The starter dose (1.5mg) is priced at $149 a month, while the highest dose (25mg) is priced at $299, almost exactly double. The mid-tier 4mg dose followed a similar upward path, rising from $149 to $199 after an introductory pricing period. That is a different pricing curve from charging the same amount for every dose strength.
A price that roughly doubles from lowest to highest dose suggests dose-based pricing rather than a flat price across strengths. If similar dose-based pricing is used in the UK, there may be a gap between the price of the 1.5mg starting dose and the 25mg maintenance dose. For pricing analysis, the maintenance-dose tablet price would be the most relevant comparison with maintenance-dose injection pricing.
Why a £99 Launch Price May Be Unlikely
One reason a £99 launch price appears unlikely is the risk of cannibalising existing Wegovy injection sales. If the tablet launched at something like £99 to £120 a month against typical maintenance-dose injection pricing of £200 to £300, some existing injection patients might ask their prescriber about changing to the lower-priced oral formulation. Any change would still need to be clinically appropriate and prescribed. From a commercial perspective, this could reduce revenue from existing customers. That is cannibalisation, a factor pharmaceutical companies may consider when launching an alternative formulation of an existing medicine.
The Rybelsus pricing evidence above reinforces this: Novo Nordisk has not historically positioned its existing oral semaglutide product as a low-cost alternative to the injectable in the UK. Rybelsus and Wegovy have different licensed indications and are not directly comparable as treatments. This does not guarantee that the new tablet will follow the same pricing pattern, but it weighs against assuming a steep discount.
At the same time, a price too close to current injection levels could limit demand among people who may prefer an oral formulation or who are sensitive to price. A £99 launch price therefore appears unlikely from a cannibalisation perspective, while a price above £280 could limit market expansion and would sit differently from the lower relative pricing seen in the US. Our estimated range sits between those possibilities, which is why our central estimate is toward the upper-middle of the range considered in this analysis.
How Might Price Affect Treatment Costs?
It is useful to illustrate the potential cost difference from a patient's perspective. These figures are illustrative only and should not be used to choose between prescription medicines. Price alone should not determine treatment choice. Any change of medicine or formulation must be clinically appropriate and agreed with a prescriber.
Take a patient currently paying £249 a month for maintenance-dose Wegovy injections. Here's what different tablet prices would mean for them:
| Tablet price | Monthly saving compared with a £249 injection |
|---|---|
| £229 | £20 |
| £199 | £50 |
| £179 | £70 |
| £149 | £100 |
| £129 | £120 |
A monthly saving of £20 to £50 may not be sufficient for some patients to consider discussing a change, particularly because the formulations have different administration requirements. A saving of £70 to £100 or more may be financially significant, but price alone should not determine whether treatment is changed.
This is one reason our commercial estimate falls within the £179 to £229 band rather than nearer £129 to £149. That range could attract new private demand while reducing the financial incentive for existing injection patients to seek a change. Any treatment change would still require clinical assessment and a prescription.
Could Mounjaro Force the Price Down?
Mounjaro (tirzepatide), made by Eli Lilly, is a major UK competitor to Wegovy. Eli Lilly raised UK Mounjaro list prices sharply from 1 September 2025. The highest-dose pen's wholesale price reportedly rose from around £122 to £330, although a rebate arrangement with UK suppliers reportedly limited the increase passed through at unit level to around £247.50. Current UK private Mounjaro pricing is commonly reported in the £120 to £340 range depending on dose and provider.
That price rise may have altered the relative price positioning of semaglutide and tirzepatide products. If Novo Nordisk wants the tablet to compete for market share rather than only serve its existing semaglutide base, there may be a commercial incentive to price it below current Mounjaro rates. This pulls in the opposite direction from the cannibalisation concern above, and only Novo Nordisk can determine how those factors will affect the final price.
What Might the NHS Pay?
Private price and NHS price are not the same number. The MHRA's approval announcement states that decisions on NHS use will follow established processes, including a NICE evaluation. Manufacturers may negotiate confidential NHS commercial arrangements, so any NHS price may differ from the private retail price. The timing and terms of any NHS access have not been confirmed.
Our UK Wegovy Pill Price Predictions
Our best estimate
If we had to guess today's launch price: £199/month
Likely range: £179 to £229
Wider range: £149 to £250
| Scenario | Monthly Price |
|---|---|
| Aggressive pricing | £120 to £149 |
| Most likely pricing | £179 to £229 |
| Premium pricing | £229 to £299 |
| Unlikely high-end scenario | £300+ |
Aggressive pricing (£120 to £149). Mirrors the lower end of confirmed US cash-pay pricing. Possible if Novo Nordisk prioritises rapid market expansion and Mounjaro competition above all else, but it sits against the Rybelsus pricing precedent and would carry meaningful cannibalisation risk.
Most likely pricing (£179 to £229). Our central estimate. This band sits below some typical UK maintenance-dose injection prices while remaining broadly consistent with how Novo Nordisk has priced its existing oral semaglutide product, Rybelsus, relative to the injectable in the UK. It could attract new private demand without creating as strong a financial incentive for existing injection patients to seek a change, and it leaves room to compete with Mounjaro without an aggressive discount.
Premium pricing (£229 to £299). Consistent with Rybelsus's historical UK pricing pattern and with prioritising injection-revenue protection over market expansion. Plausible if early tablet demand is strong enough that Novo Nordisk sees little commercial need to discount.
Unlikely high-end scenario (£300+). Would put the tablet at or above the top of current injection pricing, which we'd assign low probability given the clear discount direction in confirmed US pricing.
Why Our Estimate Could Be Wrong
A few specific things could push the eventual price outside this range: a temporary launch discount to drive early adoption; UK supply constraints in the first months pushing pharmacy-level prices up regardless of the manufacturer's price; an aggressive Mounjaro response from Eli Lilly; and dose-tiered pricing (as used in the US) meaning your actual monthly cost depends heavily on which of the four dose strengths you're on.
Frequently Asked Questions
How much will the Wegovy pill cost in the UK?
No official price has been confirmed. Our estimate is £179 to £229 per month once the tablet has launched and the market has settled, with a broader plausible range of roughly £149 to £250.
Will the Wegovy pill be cheaper than injections?
No UK price has been confirmed. It may be lower at some doses, but any comparison will depend on the dose, provider and consultation fees.
Can I get Wegovy tablets on the NHS?
Not currently. Decisions on NHS use will follow established processes, including a NICE evaluation. The timing has not been confirmed.
Is the Wegovy pill cheaper than Mounjaro?
Unknown. No UK price for the tablet has been announced, and private prices vary by dose and provider. The medicines also have different prescribing considerations, so price should not be the sole basis for treatment choice.
Why might the Wegovy pill not be much cheaper than injections?
One possible reason is cannibalisation risk, reinforced by the fact that Novo Nordisk's existing oral semaglutide product, Rybelsus, is not consistently priced below the Wegovy injection in the UK.
Is the Wegovy pill available privately in the UK right now?
No. The tablet has MHRA approval but has not commercially launched in the UK as of this update.
Will the Wegovy pill price depend on dose?
Likely. Novo Nordisk priced the four US dose strengths differently, and a similar dose-tiered structure is plausible in the UK.
Will the Wegovy pill cost less than Rybelsus?
Unknown. Rybelsus is licensed for type 2 diabetes, not weight management, so it is not a direct treatment comparator. Current private pricing does not establish how the Wegovy tablet will be priced.
Conclusion
Nobody outside Novo Nordisk knows the final UK price for the Wegovy pill. Based on confirmed US pricing, current UK Wegovy injection pricing and the UK pricing of Rybelsus, our estimate is a private monthly price most likely in the £179 to £229 range, with a broader plausible range of roughly £149 to £250. Rybelsus has a different licensed indication and is included only as a commercial pricing reference.
For planning purposes, our analysis uses around £199 a month rather than £149 a month. This remains a commercial estimate, and the actual price may be materially different.
This is a commercial pricing estimate, not an official Novo Nordisk price, financial advice or medical advice. Wegovy, Rybelsus and Mounjaro are prescription-only medicines. Treatment suitability and any change of medicine or dose must be assessed by a qualified prescriber. This article will be updated once UK pricing is confirmed.
Sources
- Medicines and Healthcare products Regulatory Agency, "First GLP-1 tablet for weight loss approved in the UK," GOV.UK, 11 June 2026
- Novo Nordisk Inc., "Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America," press release, 5 January 2026
- Wharton S, Lingvay I, Bogdanski P, et al. "Oral semaglutide 25 mg in adults with overweight or obesity." New England Journal of Medicine, 2025;393:1077 to 1087 (OASIS 4 trial)
- UK private pharmacy pricing for Wegovy, Mounjaro, and Rybelsus as reported by multiple GPhC-registered UK providers, checked June 2026
